Ebola vaccine in a nasal spray? early trial halted

NCT ID NCT03462004

Terminated ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a nasal spray vaccine against Ebola in 15 healthy adults. The vaccine uses a weakened common cold virus to deliver a piece of the Ebola virus. The study aimed to check safety and immune response, but it was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPIV3/ΔHNF/EbovZ GP vaccine (nasal spray)
What this could lead to: If successful, this could lead to a needle-free Ebola vaccine that is easier to administer in outbreaks.
What could go wrong: This was a very early (phase 1) trial with only 15 participants, and it was terminated early, so we don't have full safety or effectiveness data. The vaccine may not produce strong enough immunity or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBOLA VIRUS DISEASE

Contacts and locations

Locations

CIR Inpatient Unit, Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health

Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.